Phosphatase and tensin homolog on chromosome 10 (PTEN) is downregulated during hypertrophic and cancerous cell growth, leading to activation of the prosurvival Akt pathway. However, PTEN regulation in cardiac myocytes upon exposure to hypoxia remains unclear. We explored the role of PTEN in response to hypoxia/ischemia in the myocardium. We validated that PTEN is a transcriptional target of activating transcription factor 2 (ATF-2) and is positively regulated via a p38/ATF-2 signaling pathway. Accordingly, hypoxia-induced upregulation of phosphorylation of ATF-2 and PTEN were reversed by a dominant negative mutant p38. Inhibition of PTEN in cardiomyocytes attenuated hypoxiainduced cell death and apoptosis. Cardiac-specific knockout of PTEN resulted in increased phosphorylation of Akt and forkhead box O 1 (forkhead transcription factors), limited infarct size in animals exposed to ischemia-reperfusion injury, and ameliorated deterioration of left ventricular function and remodeling following permanent coronary artery occlusion. In addition, the activation of Bim, FASL, and caspase was coupled with PTEN activation, all of which were attenuated by PTEN inhibition. In conclusion, cardiomyocyte-specific conditional PTEN deletion limited myocardial infarct size in an in vivo model of ischemia-reperfusion injury and attenuated adverse remodeling in a model of chronic permanent coronary artery ligation. p38; activating transcription factor 2; Akt; forkhead box O 1; FAS ligand; ischemia; infarct size; reperfusion PHOSPHOINOSITIDE 3-KINASE (PI3K) phosphorylates phosphatidylinositol, producing phosphatidylinositol (3,4,5)-triphosphate (PIP3), which recruits and facilitates activation of Akt (14, 32). Phosphatase and tensin homolog on chromosome 10 (PTEN) is a dual protein-lipid phosphatase that degrades PIP3 to inactive phosphatidylinositol (4,5)-diphosphate (PIP2; Refs. 22, 26, 38, 47) and so negatively regulates the PI3K/Akt prosurvival signaling pathway. Loss or mutation of PTEN, with subsequent uncontrolled activation of the prosurvival pathways, is common in many tumors, including endometrial carcinoma, melanoma, renal, breast, prostate, and lung cancer (6, 9, 23). Dysregulation of PTEN has also been reported in heart diseases such as cardiac hypotrophy, heart failure, and ischemic heart disease (37, 46, 55, 58) . We (18) have shown that pharmacological inhibition of PTEN protects the heart against ischemiareperfusion injury through upregulation of the PI3K/Akt/endothelial nitric oxide synthase/ERK prosurvival pathway. Overexpression of PTEN increases apoptosis in neonatal cardiomyocytes, whereas expression of inactive mutant PTEN leads to Akt activation and reduces apoptosis (42). Moreover, myocardial levels of PTEN are increased in diabetic rats compared with nondiabetic rats, leading to reduced ability to phosphorylate Akt and, hence, blunting the protective effects of ischemic preconditioning (31, 52). Only two studies (41, 46) have assessed the effect of genetic deletion of PTEN on myocardial infarct size, both in an isolated heart model. Siddall et al. (46) found that although infarct size was comparable between PTEN ϩ/ϩ and PTEN Ϫ/ϩ mice, ischemic preconditioning threshold was significantly reduced in the PTEN Ϫ/ϩ mice. In contrast, Ruan et al. (41) reported that cardiac specific PTEN inactivation reduced infarct size in isolated hearts exposed to 30-min ischemia and 120 reperfusion. Thus inhibition of PTEN is a potential target for induction of protection against ischemic damage. PTEN inhibition could also be beneficial in diabetes by augmenting insulin sensitivity (32).
PHOSPHOINOSITIDE 3-KINASE (PI3K) phosphorylates phosphatidylinositol, producing phosphatidylinositol (3,4,5)-triphosphate (PIP3), which recruits and facilitates activation of Akt (14, 32) . Phosphatase and tensin homolog on chromosome 10 (PTEN) is a dual protein-lipid phosphatase that degrades PIP3 to inactive phosphatidylinositol (4,5)-diphosphate (PIP2; Refs. 22, 26, 38, 47) and so negatively regulates the PI3K/Akt prosurvival signaling pathway. Loss or mutation of PTEN, with subsequent uncontrolled activation of the prosurvival pathways, is common in many tumors, including endometrial carcinoma, melanoma, renal, breast, prostate, and lung cancer (6, 9, 23) . Dysregulation of PTEN has also been reported in heart diseases such as cardiac hypotrophy, heart failure, and ischemic heart disease (37, 46, 55, 58) . We (18) have shown that pharmacological inhibition of PTEN protects the heart against ischemiareperfusion injury through upregulation of the PI3K/Akt/endothelial nitric oxide synthase/ERK prosurvival pathway. Overexpression of PTEN increases apoptosis in neonatal cardiomyocytes, whereas expression of inactive mutant PTEN leads to Akt activation and reduces apoptosis (42) . Moreover, myocardial levels of PTEN are increased in diabetic rats compared with nondiabetic rats, leading to reduced ability to phosphorylate Akt and, hence, blunting the protective effects of ischemic preconditioning (31, 52) . Only two studies (41, 46) have assessed the effect of genetic deletion of PTEN on myocardial infarct size, both in an isolated heart model. Siddall et al. (46) found that although infarct size was comparable between PTEN ϩ/ϩ and PTEN Ϫ/ϩ mice, ischemic preconditioning threshold was significantly reduced in the PTEN Ϫ/ϩ mice. In contrast, Ruan et al. (41) reported that cardiac specific PTEN inactivation reduced infarct size in isolated hearts exposed to 30-min ischemia and 120 reperfusion. Thus inhibition of PTEN is a potential target for induction of protection against ischemic damage. PTEN inhibition could also be beneficial in diabetes by augmenting insulin sensitivity (32) .
The cardioprotective effect of PTEN inhibition is associated with restoration of Akt activity following ischemia-reperfusion injury (18) . Akt, when activated, phosphorylates two categories of downstream enzymes: the proapoptotic substrates, which are deactivated by phosphorylation, and the antiapoptotic substrates, which are activated by phosphorylation (14, 32) . Among its many actions, Akt activation leads to increased forkhead box O (FOXO) phosphorylation and promotes FOXO nuclear export, thereby inhibiting the capacity of FOXOs to upregulate proapoptotic genes (1) . Stress signaling p38 has been implicated in apoptosis and inflammation (40) and has been shown to be involved in multiple models of cardioprotection against ischemia-reperfusion injury (2) . However, its role in regulating PTEN during hypoxia or ischemia has not been reported. Here, we also assessed the role of p38 and its downstream mediator activating transcription factor 2 (ATF-2) in upregulation of PTEN in response to prolonged hypoxia in vitro.
Despite the fact that PTEN is an attractive target for myocardial protection, only a few studies assessing the role of PTEN inhibition in ischemia-reperfusion or hypoxia models have been published (18, 41, 46) . The difficulty in investigating this phosphatase relates to the lack of highly specific activators or inhibitors. We generated inducible cardiomyocyte-restricted PTEN deletion mice to study the importance of PTEN regulation in cardioprotection against ischemia-reperfusion injury and permanent coronary artery occlusion in vivo and against prolonged hypoxia in vitro. Culturing cells and exposing cells to hypoxia. Cardiomyocytes from mice were isolated using methods previously described (15) with minor modification. Mice were heparinized (5 IU/g) and anesthetized with ketamine (60 mg/kg) and xylazine (6 mg/kg) via intraperitoneal injection. Hearts were excised and cannulated via the aorta and connected to the perfusion apparatus. Hearts were perfused with MEM containing type II collagenase (Worthington Biochemical, Lakewood, NJ; 1 mg/ml) and 20 M CaCl2. After dissociation, the cardiomyocytes were differentially separated by Percoll gradient centrifugation followed by a differential preplating step for further separation of noncardiac cells. Myocytes were plated on a laminin-coated plate at a density of 2 ϫ 10 4 cells/cm 2 in media 199 (Earle's salts; Gibco-BRL) with 10% FBS and 100 U penicillin. Cardiomyocytes were then incubated at 37°C in 5% CO 2 for 24 h before experiments. Myofibroblast separated from the cardiomyocytes were isolated from the same Percoll gradient and cultured in DMEM/Ham's F-12 (1:1) supplemented with 10% FBS. Mouse embryonic stem cells (V6.5 ES cell lines) derived from C57BL/6 X 129/sv mating were cultured and maintained at 37°C in DMEM/Lif supplemented with 15% FBS. Cells between passage 4 and 7 were used for experiments. Caco-2 colon cancer cell line from ATCC (Manassas, VA) were propagated in MEM supplemented with 2.0 mM L-glutamine and 20% FBS. The culture medium was replaced by serum and glucose-free medium. Hypoxia was stimulated by adding layering mineral oil over a thin film of hypoxic media (prebubbled with N2 gas) covering the cells for the time indicated. Then, the medium was replaced by fresh medium and followed for 2 h reoxygenation.
METHODS

Animals
Western blot and malachite green assay. Samples were homogenized in modified RIPA buffer (50 mM Tris pH 7.4; 150 mM NaCl; 1 mM EDTA; 1% NP-40; 0.25% Na-deoxycholate; 1 mM PMSF; 1 g/ml of pepstatin, leupeptin, and aprotinin; 1 mm DTT; and 1 mM NaF). Equal amounts of proteins were subjected to Western blots.
The following antibodies were used: anti-AKT, anti-Thr-308 P-AKT and anti-Ser-473 P-AKT antibodies purchased from R&D Systems (Minneapolis, MN); anti-Bim, anti-p38, anti-caspase-6, anti-Pp38, anti Ser-319 P-FOXO1, anti-FOXO1, and PTEN purchased from Cell Signaling Technology (Beverly, MA); and anti-ATF-2, anti-P-ATF-2, anti-FAS ligand (FASL), and anti-␤-actin purchased from Sigma. PTEN activity was measured by immunoprecipitating heart lysates with anti-PTEN antibody, followed by incubation with protein A/G-agarose. An ELISA kit (malachite green assay kit) from Upstate (Lake Placid, NY) was used for measuring the rate of phosphate release, as previously described (18) .
Apoptotic cells detection by in situ end labeling and nuclear staining. Myocytes were seeded in chambered slides and treated with various reagents, respectively. Apoptotic cells were determined using terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) apoptosis detection kit (Roche, Indianapolis, IN) as described before (56) . The apoptotic nuclei were labeled using TUNEL assay according to the manufacturer's instructions. The nuclei of apoptotic and nonapoptotic cells were counterstained with DAPI (0.1 g/ml). The labeled cells were counted under a fluorescence microscope. The percentage of apoptotic cells was calculated as the ratio of TUNEL-positive cells to the DAPI-stained total cells, counted in six different random fields.
Real-time PCR. RT-PCR was performed by using 2 g total RNA and the following primers: mouse PTEN, forward, 5=-AATTCCCAGT-CAGAGGCGCTATGT-3=, and reverse, 5=-GATTGCAAGTTCCGC-CACTGAA CA-3=; and mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward, 5=-ACCCCCAATGTATCCGTTGT-3=, and reverse, 5=-TACTCCTTGGAGGCCATGTA-3=. The C t (threshold cycle) is defined as the number of cycles required for the fluorescence signal to exceed the detection threshold. Expression of the PTEN relative to the GAPDH was calculated as the difference between the threshold values of these two genes (2 Chromatin immunoprecipitation assay. To confirm the specificity of ATF-2 regulated PTEN expression, chromatin immunoprecipitation assays was performed using the acetyl-histone H3 chromatin immunoprecipitation assay kit (Upstate, Chicago, IL) according to the manufacturer's protocol. In brief, isolated myocytes with various treatments were first incubated with 1% formaldehyde at 37°C for 15 min to cross-link DNA-protein complexes. Cells were harvested, and cell lysates were sonicated and centrifuged to produce chromatin fragments of 300 -1000 bp in length. The supernatants were precleared with a mixture of salmon sperm DNA/protein A/protein G, followed by immunoprecipitation with anti-ATF-2 antibody-protein A-agarose slurry (with IgG serving as the negative control). The immunocomplex beads were then washed sequentially with low-salt wash buffer, high-salt wash buffer, LiCl wash buffer, and Tris-EDTA buffer. The immunocomplex was eluted with elution buffer (100 mM NaHCO3 and 1% SDS). The eluted immunocomplex and the inputs were incubated with 200 mM NaCl at 65°C overnight and followed by incubation with proteinase K to digest the remaining proteins. The DNA was recovered by the henol/chloroform/isoamyl alcohol extraction. The immunoprecipitated DNA was used as a template for PCR. The PCR products were separated by 1.5% agarose gel. The primers used for the AFT-2 binding site in the 5=-flanking region of PTEN were forward primer 5=-TCG ACT ACT TGC TTT GTA GA-3= and reverse primer 5=-TTT ACA GCC CCG ATT GGG CT-3=.
Myocardial ischemia and ischemia/reperfusion model. Treated mice (3-4 mo of age) were anesthetized with intraperitoneal injection of ketamine (60 mg/kg) and xylazine (6 mg/kg). The animals were intubated and connected to an animal ventilator (model no. 683; Harvard Apparatus, South Natick, MA) and ventilated using FIO 2 of 30%. The chest was opened, the heart was exposed, and a 7-0 nylon suture was passed under the left anterior descending coronary artery and a knot was tied on top of the tubing to occlude the artery. For the ischemia/reperfusion experiment, the left anterior descending coronary artery was occluded for the time indicated followed by a 24-h reperfusion. After reperfusion, the mice were reanesthetized, the coronary artery were reoccluded, 0.5 ml of Evan's blue dye 3% was injected into the right ventricle and the mice were euthanized under deep anesthesia. Hearts were excised and the left ventricle was sliced transversely into sections. Slices were weighed and incubated for 10 min at 37°C in 1% buffered (pH 7.4) 2,3,5-triphenyl-tetrazoliumchloride, fixed in 10% formaldehyde, and photographed to identify the ischemic area at risk (AR; uncolored by the blue dye), the infarct size (IS; unstained by 2,3,5-triphenyl-tetrazolium-chloride), and the nonischemic zones (colored by the blue dye). The area of AR and IS in each slice were determined by planimetry, converted into percentages of the whole for each slice, and multiplied by the weight of the slice. The results summed to obtain the weight of the myocardial AR and IS.
Echocardiography. For permanent coronary occlusion experiment, treated mice were anesthetized and operated as above and the coronary artery was ligated, the chest cage was then closed and pneumothorax reduced. Sham-operated animals undergoing the same open chest surgical procedure, without ЈЈbeing subjected to coronary artery ligation, served as controls. Trans-thoracic echocardiography was performed 28 days after surgery (n ϭ 8 Ϫ 10/group) under anesthesia (ketamine-xylazine, as described above) using Vevo 770 ultrasound machine equipped with a 25-MHz transducer-710B (Visualsonics-Toronto). Standard M-mode images were taken in the long axis and short axis position at the level of the papillary muscles for each animal. Key cardiac parameters, such as left ventricle internal diameters at end diastole and systole and left ventricular fractional shortening, were measured. Ejection fraction was measured by a single-plane area length using two-dimensional parasternal long axis images (19) .
Statistical analyses. Data are presented as means Ϯ SE of means. Unpaired Student t-test or ANOVA with Sidak correction for multiple comparisons were applied to compare the different groups. Values of P Ͻ 0.05 were considered statistically significant.
RESULTS
Effects of different hypoxia times on the expression and activity of PTEN.
To determine whether hypoxia has an effect on PTEN activity, we decided to examine its expression levels and activation in cardiomyocytes exposed to different duration of hypoxia. Longer periods of hypoxia (6, 12, 24 , or 48 h) induced an increase in total PTEN levels ( Fig. 1A) and PTEN Fig. 1 . Upregulation of phosphatase and tensin homolog on chromosome 10 (PTEN) induced by hypoxia. A and B: myocytes were exposed to hypoxia for increasing intervals as indicated. PTEN protein levels and activity were examined by Western blot and malachite green assay, respectively. *P Ͻ 0.02 vs. normoxia [0 hypoxia (h)]; n ϭ 4 in each group. C and D: 12-wk-old C57bl/6 mice were subjected to coronary artery occlusion (CAO) for the intervals indicated. Myocardial tissue from the ischemic and nonischemic (remote) zone, were subjected to Western blot and malachite green analysis. Shamoperated mice were served as control. n ϭ 4 in each group, Error bars represent Ϯ SE. *P Ͻ 0.05 vs. sham. E and F: myofibroblasts, Mouse embryonic stem cell lines (V6.5 ES), and Caco-2 cells were exposed to hypoxia for the indicated durations. PTEN expression was analyzed by Western blot. n ϭ 4 in each group. Error bars represent Ϯ SE. *P Ͻ 0.05 vs. normoxia [0 hypoxia (h)]. activity (Fig. 1B) . However, during short intervals (30 min) of hypoxia, PTEN expression and activity were reduced. Similarly, after 15 min of coronary artery occlusion in vivo in mice, PTEN expression (Fig. 1C) and activity (Fig. 1D) were decreased in the ischemic region compared with the nonischemic zone or heart tissue from sham-operated mice. However, during longer periods of ischemia (6 or 12 h), both PTEN expression level and activity were dramatically increased. These data suggest that long-term hypoxia induces upregulation of PTEN, which may mediate inhibition of Akt. On the other hand, short time exposure to hypoxia induced ischemic preconditioning, which is mediated by increased Akt activity.
We also examined the effects of duration of hypoxia on the expression of PTEN in two other cell types. Oxygen tension is an important stimulus in stem cell and cancer cell biology and plays a role in cellular proliferation and differentiation. Therefore, we investigated the effect of hypoxia on V6.5 ES (mouse embryonic stem cells) cells and Caco-2 (colon cancer) cells. Interestingly, both Caco-2 and V6.5 ES cell lines exhibited slightly decrease in PTEN after 48 h of hypoxia ( Fig. 1, E and  F) . However, fibroblasts isolated from mice hearts (myofibroblasts) exhibited a significant upregulation of PTEN after 24 and 48 h of hypoxia. These differences between cell types may reflect a contrast in their tolerance to hypoxia, cancer or stem cells being more resistant.
Upregulation of PTEN is mediated by p38 pathway during hypoxia. We next investigated the mechanisms by which hypoxia induced the upregulation of PTEN. The mitogen-activated protein kinase p38 can be activated in response to a wide variety of stimuli and stress responses in the development of cardiovascular diseases (7, 10, 12, 24, 28) . We examined p38 expression and phosphorylation levels in cardiomyocytes exposed to hypoxia and the effect of p38 on PTEN expression during hypoxia. Cardiomyocytes were subjected to 0, 6, 12, 24, and 48-h hypoxia and 2-h reoxygenation. Hypoxia induced phospholation of p38 (Fig. 2, A and B) . We also examined cardiomyocytes transfected with dominant-negative p38 produced by mutagenesis of two phosphorylation sites of p38 (180T/A and 182Y/F). Activation of p38 was accompanied by upregulation of PTEN (Fig. 2, C and D) . In contrast, inactivation of p38 by domain negative p38 adenoviruses (DNp38) did not inhibit the basal levels of PTEN in cardiomyocytes but Fig. 2 . Upregulation of PTEN is mediated by p38 pathway during hypoxia. A and B: total and phosphorylated p-38 protein levels were examined by Western blot in myocytes exposed to hypoxia for the indicated durations. *P Ͻ 0.05 vs. normoxia [0 hypoxia (h)]; n ϭ 4 in each group. C and D: myocytes were transfected with domain negative p38 (DN-p38) adenoviruses (50 plaque-forming unit/cell) or vector for 24 h and exposed to hypoxia for the indicated durations. PTEN and phosphorylated p38 proteins were assessed by Western blot. *P Ͻ 0.05 vs. vector [0 hypoxia (h)]; #P Ͻ 0.05 vs. vector 24-h hypoxia; n ϭ 4 in each group. E and F: myocytes were treated with 20 M p38 inhibitor SB203580 (SB) for 2 h and followed by hypoxia for the indicated durations. PTEN and phosphorylated p38 proteins were assessed by Western blot. *P Ͻ 0.05 vs. vector 24-h hypoxia; #P Ͻ 0.05 vs. vector 48-h hypoxia; n ϭ 4 in each group. G: real-time PCR analyses of PTEN mRNA expression in cardiomyocytes treated as described in C and D. PTEN mRNA level was increased by hypoxia, and this response was blocked by the dominantnegative p38. *P Ͻ 0.05 vs. vector 0 h; #P Ͻ 0.0001 vs. vector 24 h. completely suppressed PTEN upregulation after exposure to 24-h hypoxia. Pharmacologic inhibition of p38 by SB203580 resulted in inactivation of p38 and downregulation of PTEN (Fig. 2, E and F) after 24-h and 48-h hypoxia. In addition, DNp38 prevented the hypoxia induced increase in PTEN mRNA (Fig. 2G) . These data suggest that p38 is involved in mediating hypoxia-induced PTEN activation by upregulating PTEN transcription and expression.
p38-target transcriptional factor ATF-2 mediates PTEN upregulation in hypoxia. p38 is involved in gene regulation by activating transcriptional factors such as monocyte-specific enhancer factor 2 and cAMP-responsive element-binding proteins (CREBPs; Ref. 50). ATF-2 is a transcription factor that is regulated by JNK/p38 in response to various stress stimuli (39, 43, 57) . To further investigate the mechanisms by which p38 mediates hypoxia-induced PTEN mRNA upregulation, we tested the effect of ATF-2 on PTEN gene transcription during hypoxia. Activation of ATF-2 followed the same pattern as P-p38 and PTEN in response to hypoxia (Fig. 3A) . Inhibition of p38 expression by DNp38 resulted in lower levels of phosphorylated ATF-2 in response to hypoxia (Fig. 3B) , indicating that ATF-2 is a target of activated p38. Inhibition of ATF-2 by shRNA prevented hypoxia-induced increase in PTEN mRNA levels (Fig. 3C ). ATF-2 belongs to the ATF/CREBP family of transcription factor. It binds to the target DNA either as homodimers or as heterodimers together with CREBP or AP-1 transcription factors. The promoter region of the PTEN gene contains two putative ATF-2 half-binding sites: site 1, cctTGACGggtggg; and site 2, ggcTGACGgccatt (Fig.  3D) . We assessed the specific binding activity of ATF-2 on PTEN promoter region using chromatin immunoprecipitation assays. The chromatin immunoprecipitation assay confirmed that ATF-2 binding to site 1 of the PTEN promoter was significantly increased by hypoxia (Fig. 3E) , suggesting that ATF-2 is involved in hypoxia-induced PTEN transcription. p38 inhibition significantly reduced the binding activity, where negative control with a promoter region distant from the binding sites, and control without using ATF-2 antibody had no effect.
Knockdown of PTEN attenuates hypoxia-induced apoptosis. Cardiomyocytes from PTEN loxp/loxp mice were incubated with adenovirus (AV)-Cre (50 plaque-forming units/cell) or AVmock (50 plaque-forming units/cell, served as control) for 24 h before hypoxia. Immunofluorescent staining showed that 92% of these cells were myocardial myosin-positive cells (Fig. 4A) . Transfection with AV-Cre effectively knocked down PTEN expression. The intact and PTEN deleted cardiomyocytes were subjected to different durations of hypoxia (0, 6, 12, and 24 h). PTEN activity increased during hypoxia in the AV-mocktreated cells (AV-CreϪ). PTEN activation was significantly attenuated in the AV-Cre-treated cells (Fig. 4B) . Twenty-fourhour hypoxia increased PTEN protein levels in the AV-mock treated cells. PTEN deletion by AV-Cre transfection markedly increased P-AKT levels at baseline and after 24 h of hypoxia (Fig. 4, C and D) . Cell death was assessed by trypan blue uptake. Inhibition of PTEN by AV-Cre reduced cell death (Fig.  4E ) compared with AV-mock (AV-CreϪ). Apoptosis was assessed using a TUNEL kit. Consistently, PTEN inhibition attenuated apoptosis induced by hypoxia (Fig. 4F) . These results clearly indicate that PTEN inhibition plays an important role in cardiac protection by preventing apoptosis.
Knockout of PTEN ameliorates ischemic damage and heart failure in vivo.
To investigate the role of PTEN inhibition in the heart in vivo, the PTEN loxp/loxp/cre progeny was used. No abnormal phenotypes were observed. PTEN loxp/loxp/cre and PTEN loxp/loxp mice were treated with tamoxifen. Cardiac-specific deletion of PTEN (PTEN CKO ) was confirmed by immunobloting (Fig. 5, A and B) , and immunofluorescence (Fig. 5C ). PTEN expression was significantly reduced. However, intact PTEN was still detectable in cardiomyocytes from tamoxifen treated PTEN loxp/loxp/cre mice, suggesting that the Cre-mediated recombination at the floxed PTEN allele was incomplete as previously observed (41) . Mice underwent 45-min coronary artery occlusion followed by 24-h reperfusion. PTEN CKO mice had smaller infarct size (20.5 Ϯ 0.8%) compared with the tamoxifen-treated PTEN loxp/loxp mice (43.7 Ϯ 3.2%) or vehicle-treated PTEN loxp/loxp/cre mice (45.5 Ϯ 1.7%; P Ͻ 0.05.). To explore the effect of PTEN inhibition in a model of permanent coronary artery occlusion without reperfusion, cardiac dimensions and function were analyzed. Four weeks after permanent left coronary artery occlusion, heart sections showed a less dilated left ventricular chamber in the PTEN CKO compare to control mice (Fig. 6A) . Left ventricular weight-tobody weight ratio and heart weight-to-body weight ratio increased in the control mice with permanent coronary artery occlusion compared with the sham-operated mice (Fig. 6 , B and C). However, in the PTEN CKO mice these increases were completely attenuated. Echocardiography showed that the left ventricular end diastolic diameter, end systolic diameter, ejection fraction, and fractional shortening, were better preserved in the PTEN CKO compared with the control group (Fig. 6D ). In addition, there was less collagen deposition, which is a reflection of reduced cardiomyocytes death and myofibroblast proliferation (Fig. 6, E and F) .
In the sham-operated mice, PTEN levels were much lower in the myocardium of PTEN CKO mice compared with control (Fig. 7, A and B) . PTEN levels were increased in the myocardial infarct zone of control mice subjected to permanent coronary artery occlusion (Fig. 7, A and B) . P-Akt levels were higher in PTEN CKO mice than in control, both in mice not subjected and those who were subjected to coronary artery occlusion (Fig. 7, A and C) , whereas levels of total Akt were not affected by coronary artery occlusion or knocking down PTEN (Fig. 7A) . Phosphorylation of FOXO1 was increased in the PTEN CKO mice compared with the control mice, both in mice not subjected and those who were subjected to coronary artery occlusion (Fig. 7, A and D) , whereas total FOXO1 levels were not affected by knocking down PTEN or coronary artery occlusion (Fig. 7A) . We also confirmed that knocking down PTEN prevented the increase in the proapoptotic mediators FASL (Fig. 7, E and F) , Bim (Fig. 7, E and G) , and caspase-6 (Fig. 7, E and H) compared with control mice following coronary artery occlusion.
DISCUSSION
Considerable research has been undertaken to investigate the possibility of increasing cell survival and reducing cell death following hypoxia or ischemia/reperfusion. Studies (13, 14) have shown the essential role of PI3K in activating Akt with downstream activation of the prosurvival kinases and suppression of the proapoptotic pathways. However, PTEN has equal role in determining PI3P levels and, hence, Akt activation (32) . The role of PTEN in determining the aggressiveness and behavior of tumor cells is well established. Deletion and downregulation of PTEN are detected in various human cancers and are associated with more aggressive tumor behavior, including a tendency to metastasize (20, 53, 54) . However, the role of PTEN in determining the response to myocardial ischemia is less established.
We are showing in the present study that brief periods of hypoxia, which usually do not result in cell death, induced downregulation of PTEN in cardiomyocytes, which is consistent with the results seen following ischemic preconditioning Fig. 3 . p38-target transcriptional factor activating transcription factor 2 (ATF-2) mediated PTEN upregulation in hypoxia. A: total and phosphorylated ATF-2 protein levels were examined by Western blot in cardiomyocytes exposed to hypoxia for indicated durations. *P Ͻ 0.05 vs. normoxia [0 hypoxia (h)]; n ϭ 4 in each group. B: cardiomyocytes were transfected with domain negative p38 adenoviruses (DN-p38) or vector for 24 h and followed by hypoxia for indicated durations. ATF-2 and phosphorylated ATF-2 proteins were assessed by Western blot. *P Ͻ 0.05 vs. vector 0-h hypoxia; #P Ͻ 0.05 vs. vector 24-h hypoxia; n ϭ 4 in each group. C: cardiomyocytes were transfected with shRNA against ATF-2 or vector for 24 h and followed by hypoxia at indicated durations. PTEN expression was analyzed by real-time PCR. *P Ͻ 0.05 vs. vector [0 hypoxia (h)]; #P Ͻ 0.05 vs. vector 24-h hypoxia; n ϭ 4 in each group. D: ATF/cAMP-responsive element-binding protein (CREBP) sites in the PTEN promoter region are illustrated. E: specifically bound DNA was amplified by PCR. Hypoxia increased the binding of ATF-2 to ATF/CREBP site in the PTEN promoter. Protein-DNA complex cross-linked by formaldehyde was immunoprecipitated using anti-ATF-2 antibody. NC1, negative control with a promoter region distant from the binding sites; NC2, negative control without using ATF-2 antibody.
(5). On the other hand, when the duration of ischemia is extended, PTEN was upregulated. This suggests that prolonged ischemia may trigger the switch from prosurvival pathways to the insult that activates cell death pathways. We also observed a similar upregulation in isolated cardiac myocytes and myofibroblasts after prolonged hypoxia. In contrast, the V6.5 ES cell line and Caco-2 colon cancer line exhibited a slight decrease in PTEN in response to hypoxia. This suggested that different signaling pathways and mechanism were triggered in response to hypoxia in cardiomyocytes and myofibroblasts vs. ES cells and cancer cells. It is plausible that due to higher energy requirements, cardiac cells are more susceptive to ischemia and switch to pro-death state earlier than more resistant cells.
In searching for the mechanisms leading to upregulation of PTEN in response to hypoxia, we found that PTEN upregulation was paralleled with activation of stress signaling kinase p38. Activation of p38 is induced by multiple cellular stresses including oxidative stress, ischemia-reperfusion injury, and osmotic stress (2, 48) . Inhibition of p38 during ischemia reduces ischemia-reperfusion injury and limits infarct size (3, 25, 34) . Disruption of a single copy of the p38 MAP␣ kinase gene leads to cardioprotection against ischemia-reperfusion injury (36) . Ischemic preconditioning attenuates p38 activation during sustained ischemia (27) . It has been suggested that inhibition of p38 mediates the protective effect of postconditioning (49) . In the present study, we are confirming that hypoxia induced p38 phosphorylation. Moreover, we discovered that hypoxia-induced PTEN upregulation was blocked by inhibition of p38 activation. Thus PTEN is the link between hypoxia-induced p38 activation and cell death. Furthermore, we showed that p38 targets transcriptional factor ATF-2 that binds to ATF sites in the PTEN promoter. Our findings are in agreement with Barancik et al. (3) , who found that SB203580, a specific inhibitor of p38, prevents ischemia-induced phosphorylation of nuclear ATF-2. Hypoxia enhanced ATF-2 phosphorylation and its binding activity to PTEN promoter, increasing PTEN transcription. These results indicated that ATF-2 is a critical link between the p38 stress signaling and PTEN gene expression in response to hypoxia.
We (18) have previously shown that pharmacological inhibition of PTEN with BpV(HOpic) attenuated cell death and reduced apoptosis in adult rat cardiomyocytes exposed to hypoxia-reoxygenation. Moreover, BpV(HOpic) reduced myocardial infarct size in vivo in rats subjected to 30-min ischemia/4-h reperfusion, when administered either before ischemia or just before reperfusion (18) . Left ventricular function (assessed by echocardiography at 7 and 28 days after infarction) was improved in rats treated with BpV(HOpic) compared with control rats (18) . Inhibiting PTEN resulted in higher myocardial levels of P-Akt, P-Erk ) mice. Immunofluorescent staining showed that 92% of these cells were myocardial myosin-positive cells. B: cardiomyocytes were transfected with adenovirus-Cre (AV-Cre; 50 plaque-forming unit/cell) for 24 h. Intact and PTEN-deleted myocytes were subjected to hypoxia at indicated durations. PTEN activity was analyzed by malachite green analysis. *P Ͻ 0.05 vs. vector (AV-CreϪ); n ϭ 4 in each group. C and D: cardiomyocytes were transfected with AV-Cre for 24 h and followed by hypoxia for indicated durations. PTEN, p-Akt, and total Akt protein levels were analyzed by Western blot. *P Ͻ 0.05 vs. AV-CreϪ 0-h hypoxia; #P Ͻ 0.05 vs. AV-CreϪ 24-h hypoxia; n ϭ 4 in each group. E and F: cardiomyocytes were transfected with AV-Cre for 24 h and followed by hypoxia for indicated durations. Cell death and apoptosis were accessed by trypan blue and terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL), respectively. *P Ͻ 0.05 vs. AV-CreϪ; n ϭ 4 in each group. 1/2, and P-endothelial nitric oxide synthase, and reduced caspase-3 activity and BAX activation (18) .
The current study differs from the previous in several aspects. In the previous study, we used pharmacologic inhibition with BpV(HOpic) that caused transient inhibition of PTEN in all cell types and organs. Here we used genetic induction of PTEN deletion, limited to cardiomyocytes, whereas PTEN remained intact in other cell types. Moreover, in the present study we assessed the chronic effects of PTEN deletion in a model of permanent coronary artery occlusion in addition to ischemia-reperfusion injury model. In the current study, we are showing that with prolonged ischemia that results in cell death PTEN expression and activity increased. Cardiac-specific PTEN knockout increased cell survival and reduced apoptosis in response to hypoxia-reoxygenation in vitro and ischemiareperfusion in vivo. Moreover, PTEN deletion was associated with dramatic improvement in left ventricular remodeling and function in an in vivo model of permanent coronary artery occlusion, suggesting that protection by PTEN deletion extends beyond the one achieved by ischemic preconditioning, as the protective effects of ischemic preconditioning vanished when ischemia is prolonged (35) . As we did not actually measure infarct size after 4 wk; unfortunately, we cannot determine whether the improved in function seen at 4 wk is related to smaller infarct size or better remodeling in the noninfarcted zones. It has been shown that partial genetic inactivation of PTEN (PTEN ϩ/Ϫ ) facilitates ischemic preconditioning in an isolated heart model (46) . Infarct size following 35 min-ischemia/30-min reperfusion was comparable between PTEN ϩ/Ϫ and PTEN ϩ/ϩ mice. However, the threshold of ischemic preconditioning was significantly reduced in the PTEN ϩ/Ϫ mice (46) . These results suggested that more complete inhibition of PTEN is needed to mediate protection. Indeed, Ruan et al. (41) , using a similar model of cardiomyocyte-specific conditional PTEN deletion, showed that PTEN deletion reduced infarct size in isolated hearts exposed to 30-min ischemia/120-min reperfusion. In the present study, we have extended these reports on the beneficial effects of PTEN deletion using an in vivo model of cardiac-specific conditional PTEN deletion, showing that myocardial infarct size was reduced after ischemia-reperfusion injury and that myocardial fibrosis, cardiac function, and remodeling were improved in a model of permanent coronary artery ligation.
Interestingly, we found that knocking down PTEN resulted in less fibrosis in the infarcted area without evidence of hypertrophy or fibrosis in the remote zones. It has been suggested that long-term inhibition of PTEN may lead to uncontrolled Akt activation with subsequent left ventricular hypertrophy, fibrosis, and left ventricular dysfunction (8, 21, 30, 37, 42 and function 3 wk after cardiomyocyte-specific PTEN knockdown with tamoxifen. Chronic PTEN deletion may lead to prolonged Akt activation. It was reported that long-term Akt activation (Ͼ2-3 mo) contributes to the progression from adaptive hypertrophy to heart failure (45) . Thus we cannot exclude that with longer observation time hypertrophy and fibrosis would occur. However, it might be that when PTEN deletion is limited to the cardiomyocytes, leaving PTEN intact in other cells including myofibroblasts, adverse remodeling and hypertrophy may not occur.
PTEN is a dual protein-lipid phosphatase that inhibits prosuvival pathways PI3K/Akt. Among its many actions, Akt activation leads to increased FOXO phosphorylation at Ser-319 and promotes FOXO export from the nucleus, thereby inhibiting the capacity of FOXOs to upregulate proapoptotic genes (1, 4, 17, 29) . Nuclear translocation of FOXO1 is reported to activate apoptosis in cardiomyocytes (44) . However, the exact role of FOXO1 in inducing apoptosis and cell death following ischemia-reperfusion is unclear, as several reports have suggested a protective role for FOXO1. It was suggested that the infarct size-limiting effects of Sirt1 are dependent on nuclear translocation of FOXO1 with subsequent upregulation of manganese superoxide dismutase (MnSOD) and suppression of oxidative stress (16) . Sirt1-mediated upregulation of MnSOD was significantly attenuated in the presence of FoxO1 knockdown in cultured cardiac myocytes (16) . It was also reported that infection of cardiomyocytes with a dominant-negative FOXO1 adenovirus resulted in an increase in reactive oxygen species and cell death upon induction of oxidative stress (44) . On the other hand, overexpressing FOXO1 reduces reactive oxygen species and cell death (44) . Furthermore, mice with combined conditional deletion of FOXO1 and FOXO3 in Fig. 6 . Cardiomyocyte-specific knockout of PTEN attenuates left ventricular remodeling in a model of permanent coronary artery ligation. A: 12-wk-old PTEN CKO and control mice were subjected to chronic left CAO or a sham operation. After 4 wk, isolated hearts were sectioned to reveal the extent of left ventricular chamber dilatation (n ϭ 5 in each group). B and C: left ventricle weight-to-body weight ratio (LVW/BW) and heart weight-to-body weight ratio (HW/BW) were calculated. *P Ͻ 0.05 vs. sham; n ϭ 10 in each group. D: left ventricular internal end diastolic (LVIDd) and systolic (LVIDs) diameters (mm), ejection fraction (EF; %), fractional shortening (FS; %) and heart rat (HR; beats/min) were assessed by echocardiography 4 wk after permanent coronary artery ligation. *P Ͻ 0.02 vs. sham of matching genotype; #P Ͻ 0.05 control vs. CAO; n ϭ 12 in each group. E: hearts were fixed in formaldehyde, sectioned, and stained with Masson-trichrome staining for detection of collagen (blue). F: collagen content was quantified (n ϭ 4 in each group, 4 sections each) as a percentage of the total area. *P Ͻ 0.02 vs. sham of matching genotype; #P Ͻ 0.05 control vs. CAO.
cardiomyocytes, subjected to 1-h ischemia/24-h reperfusion, had a larger infarct size and the expression of antiapoptotic molecules PTEN-induced kinase-1 and CBP/P300-interacting transactivator was decreased compared with controls with intact FOXO1 and FOXO3 (44) . Moreover, permanet ligation of the coronary artery resulted in a larger scar formation, reduced cardiac function, and increased apoptosis in mice with cardiomyocye-specific conditional loss of both FOXO1 and FOXO3 (44) . These results suggest that FOXO1 has a protective role against ischemia/reperfusion injury. Here we showed that PTEN inhibition caused activation of the Akt pathway and deactivation of FOXO1 (FKHR 1) in the infarct region of the ischemic heart. The FOXO family of transcription factors is active in regulating the expression of proapoptotic cytokines and signaling intermediates. Active FOXO1 causes apoptosis, and this outcome is dependent on FOXO-DNA binding (51) . The proapoptotic function of FOXO1 is mediated through transcription of several target genes, including FASL (4), Bim (11) , and TRAIL (33) . In the current study, we investigated the effect of inhibition PTEN on FOXO1 and its downstream Bim and FASL in response to permanent coronary artery ligation. In our cardiac-specific knockout model, inhibition of PTEN significantly increased FOXO1 phosphorylation and decreased the proapoptotic signaling Bim and FASL during ischemia. Accordingly, activation of caspase-6 in the infarct zone was attenuated in the PTEN CKO mice. In conclusion, we have shown that genetic conditional deletion of PTEN limited to cardiomyocytes reduced cell death and apoptosis in vitro and limited myocardial infarct size in an in vivo model of ischemia-reperfusion. Moreover, cardiomyocyte PTEN deletion improved left ventricular remodeling and limited fibrosis in a model of chronic permanent coronary artery occlusion, without inducing hypertrophy or fibrosis in sham-operated animals. Hypoxia-induced PTEN upregulation is dependent on p38/ATF-2 activation. PTEN inactivation leads to upregulation of Akt and FOXO1 phosphorylation and inactivation of the proapoptotic FASL, Bim, and caspase-6.
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